Dr. Swetha Kambhampati, MD | Duarte, CA ...

Dr. Swetha Kambhampati, MD

Claim this profile

City of Hope Medical Center

Studies Cancer
Studies Follicular Lymphoma
6 reported clinical trials
8 drugs studied

Area of expertise

1Cancer
Swetha Kambhampati, MD has run 6 trials for Cancer. Some of their research focus areas include:
Stage IV
CD19 positive
CD20 positive
2Follicular Lymphoma
Swetha Kambhampati, MD has run 4 trials for Follicular Lymphoma. Some of their research focus areas include:
CD19 positive
CD20 positive

Affiliated Hospitals

Image of trial facility.
City Of Hope Medical Center
Image of trial facility.
City Of Hope At Irvine Lennar

Clinical Trials Swetha Kambhampati, MD is currently running

Image of trial facility.

Lenalidomide + Epcoritamab

for Follicular Lymphoma

This phase II trial tests how well lenalidomide and epcoritamab works in treating patients with follicular lymphoma that has not been previously treated. Although follicular lymphoma is incurable, prognosis has improved for both early and advanced stage disease, largely attributed to therapeutic advances. Lenalidomide may stimulate or suppress the immune system in different ways and stop cancer cells from growing and by preventing the growth of new blood vessels that cancer cells need to grow. Epcoritamab is a bispecific monoclonal antibody that binds to two different antigens (the part of the target that the antibody attaches to), at the same time. This dual action allows bispecific antibodies to improve target specificity by binding two antigens on the same cell to recruit and activate immune cells to kill cancer cells. Lenalidomide and epcoritamab, when given together, may be more effective in treating patients with follicular lymphoma than if they were given alone.
Recruiting1 award Phase 224 criteria
Image of trial facility.

Epcoritamab + Tazemetostat

for Follicular Lymphoma

This phase II trial tests the safety, side effects and effectiveness of epcoritamab and tazemetostat in treating patients with grade I-IIIa follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab is a bispecific monoclonal antibody that binds to two different antigens on the surface of cancer cells that may help the body's immune system attack the cancer and may interfere with the ability of the cancer cells to grow and spread. Tazemetostat, a EZH2 inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving epcoritamab and tazemetostat may be safe, tolerable and/or effective in treating patients with relapsed or refractory grade I-IIIa follicular lymphoma.
Recruiting1 award Phase 29 criteria

More about Swetha Kambhampati, MD

Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Swetha Kambhampati, MD has experience with
  • Epcoritamab
  • Lenalidomide
  • Tazemetostat
  • Loncastuximab Tesirine
  • Mosunetuzumab
  • PRO1160

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Swetha Kambhampati, MD specialize in?
Swetha Kambhampati, MD focuses on Cancer and Follicular Lymphoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are CD19 positive.
Is Swetha Kambhampati, MD currently recruiting for clinical trials?
Yes, Swetha Kambhampati, MD is currently recruiting for 4 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Swetha Kambhampati, MD has studied deeply?
Yes, Swetha Kambhampati, MD has studied treatments such as Epcoritamab, Lenalidomide, Tazemetostat.
What is the best way to schedule an appointment with Swetha Kambhampati, MD?
Apply for one of the trials that Swetha Kambhampati, MD is conducting.
What is the office address of Swetha Kambhampati, MD?
The office of Swetha Kambhampati, MD is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.